Sun Pharma’s arm inks agreement for divestment of its two manufacturing facilities

06 Jun 2016 Evaluate

Sun Pharmaceutical Industries’ wholly owned subsidiaries has entered into an agreement with Frontida BioPharm, Inc. (Frontida) for divestment of its two oral solid dosage manufacturing facilities located at Philadelphia, PA, and Aurora, IL both in the US, along with 15 related pharmaceutical products. This step taken by the company is part of its manufacturing consolidation in the US.

In connection with the transaction, Frontida has agreed to continue manufacturing certain products for Sun Pharma at these facilities on a contract basis for a predetermined period. It has also agreed to offer employment to all production, quality and administrative personnel at the sites. During the divestment process, Sun Pharma was cognizant about ensuring the continued supply of quality products to patients and protecting the interests of its employees working in these units. The impact of this development on Sun Pharma’s consolidated financials and operations is not material.

Sun Pharma is the world’s fifth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.



Sun Pharma Inds. Share Price

1717.30 -1.90 (-0.11%)
29-Dec-2025 15:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.30
Dr. Reddys Lab 1268.00
Cipla 1493.10
Zydus Lifesciences 904.25
Lupin 2078.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×